

# Behavioral Health Quality Index Measures RY2018

MY = Measurement Year, usually the calendar year prior to HEDIS reporting season (PY is the year prior to MY)

	Name of HEDIS Measure	Who code (Denominator)	Who Experience (Event/Diagnosis - Denominator)	Measured Service or Outcome (Numerator)	Medical Records Should Document	Changes Notable for Providers RY18	NOTES	
	<b>Behavioral Health Quality Index (New)</b>	Follow-Up Care for Children Prescribed ADHD Medications	ADD	6-12 years old between 3/1 PY and 2/28 MY	1) Initiation Phase - new dispense of ADHD medication (no evidence of medication in four months prior to dispensing date) 2) Continuation and Maintenance Phase - remain on medication for at least 210 days	1) Initiation Phase - at least one followup visit with practitioner with prescribing authority within 30 days 2) Continuation and Maintenance Phase - at least two follow-up visits with a practitioner within 270 days after Initiation Phase ends (day 31-300)	N/A (compliance determined by administrative data like claims)	Added telehealth; clarified that visits must be on different dates
Follow-Up After Hospitalization for Mental Illness		FUH	6+ years old at discharge	Acute inpatient discharge with principal diagnosis of mental illness between 1/1 and 12/1 of MY	1) Follow-up visit with a mental health practitioner within 7 days after discharge 2) Follow-up visits with a mental health practitioner within 30 days after discharge	N/A (compliance determined by administrative data like claims)	Added telehealth modifiers.	Measure applies to each discharge; members may have more than one discharge during the measurement period.
Antidepressant Medication Management		AMM	18+ years old	Dispensed antidepressant medication with an encounter with diagnosis of major depression from 121 days prior to date of earliest dispensing event through 60 days after the date of the earliest dispensing event, with no history of antidepressant medication 105 days prior to the earliest dispensing event.	Acute Phase - 84+ days (12 weeks) of treatment with antidepressant medication between earliest dispensing date through 114 days after earliest date (allows gap of 31 days) Continuation Phase - 180+ days (6 months) of antidepressant treatment from earliest dispensing date through 231 days after earliest date (allows gap of 52 days within the 232-day period)	N/A (compliance determined by administrative data like claims)	Telehealth modifiers and phone visits remain in the eligible population.	None
Metabolic Monitoring for Children/Adolescents on Antipsychotics		APM	1-5; 6-11; 12-17 years old	2+ Antipsychotic dispensing events	Metabolic testing including both: 1) at least one blood glucose or HbA1c test and 2) at least one LDL-C or cholesterol test	N/A (compliance determined by administrative data like claims)	No	None
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment		IET	13+ as of 12/31 with a new episode of AOD	New diagnosis of AOD abuse or dependence (no evidence of AOD diagnosis within 60 days before first diagnosis in intake period of 1/1 - 11/15)	1) Initiate treatment within 14 days of diagnosis 2) Initiate treatment and have 2+ additional services within 34 days of initiation visit	N/A (compliance determined by administrative data like claims)	Added dispensing of medication-assisted treatment and telehealth. Extended the engagement timeframe from 30 days to 34 days.	Treatment could be inpatient AOD admission, outpatient visit, intensive outpatient visit or partial hospitalization, telehealth or medication assisted treatment (MAT).
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics		APP	1-5; 6-11; 12-17 years old	New prescription for antipsychotic medication	Psychosocial care	N/A (compliance determined by administrative data like claims)	Added telehealth	None